Meta-Analysis of Preadmission Metformin Use and Mortality in Diabetic Sepsis Patients

A systematic review and meta-analysis of 14 studies comprising 12,687 patients, conducted by Mingying Zhang and last updated in April 2026. It aggregates evidence from cohort studies sourced from MEDLINE, EMBASE, and Cochrane CENTRAL databases. The analysis evaluates the association between preadmission metformin use and mortality outcomes in patients with sepsis and diabetes.

Use Cases

• Assessing the prognostic value of metformin history based on pooled mortality odds ratios.
• Evaluating time-specific mortality outcomes (e.g., 28-day, 90-day) based on the reported meta-analysis results.
• Investigating the relationship between metformin use and secondary clinical markers like serum creatinine and lactate levels.

Strengths

• Includes data from 14 studies with a total of 12,687 patients, providing a substantial sample for meta-analysis.
• All included studies were assessed as having a low risk of bias using the Newcastle–Ottawa Scale.
• Reports specific pooled odds ratios and confidence intervals for multiple mortality time points (e.g., 28-day, 90-day, in-hospital).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying aggregated data is unknown, which may limit suitability assessment.
• Data may reflect publication or selection bias inherent to the systematic review's source studies.

Provenance

Source

Mingying Zhang via figshare.

Collection Method

Systematic review and meta-analysis of cohort studies from MEDLINE (via PubMed), EMBASE, and Cochrane CENTRAL.

Time Range

Studies from database inception to September 1, 2025.

Freshness

Last updated 2026-04-20 04:13:27; freshness should be verified.